Report cover image

Bronchodilators Market by Drug Class (Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, Xanthine Derivative), Route of Administration (Injectable, Nasal, Oral), Disease, End-users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 198 Pages
SKU # IRE18436514

Description

Bronchodilators Market by Drug Class (Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, Xanthine Derivative), Route of Administration (Injectable, Nasal, Oral), Disease, End-users - Global Forecast 2024-2030


The Bronchodilators Market size was estimated at USD 18.37 billion in 2023 and expected to reach USD 19.20 billion in 2024, at a CAGR 5.98% to reach USD 27.59 billion by 2030.

Global Bronchodilators Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bronchodilators Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bronchodilators Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bronchodilators Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AMGIS Lifescience Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Siemens Healthcare GmbH, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Vectura Group PLC, and Zydus Group.

Market Segmentation & Coverage



This research report categorizes the Bronchodilators Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Anticholinergic Bronchodilators
Beta-Adrenergic Bronchodilators
Xanthine Derivative
Route of Administration
Injectable
Nasal
Oral
Disease
Asthma
COPD
End-users
Hospitals
Specialty Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bronchodilators Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bronchodilators Market?
3. What are the technology trends and regulatory frameworks in the Bronchodilators Market?
4. What is the market share of the leading vendors in the Bronchodilators Market?
5. Which modes and strategic moves are suitable for entering the Bronchodilators Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

198 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Bronchodilators Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of respiratory disorders worldwide
5.1.1.2. Growing awareness about asthma and cystic fibrosis respiratory disorders
5.1.2. Restraints
5.1.2.1. Huge expenditure required for treating chronic bronchitis
5.1.3. Opportunities
5.1.3.1. Robust research activities to develop noval bronchodilators
5.1.3.2. Increasing number of clinical trials to treat chronic bronchitis
5.1.4. Challenges
5.1.4.1. Side effects associated with consumption of bronchodilators
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Bronchodilators Market, by Drug Class
6.1. Introduction
6.2. Anticholinergic Bronchodilators
6.3. Beta-Adrenergic Bronchodilators
6.4. Xanthine Derivative
7. Bronchodilators Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Nasal
7.4. Oral
8. Bronchodilators Market, by Disease
8.1. Introduction
8.2. Asthma
8.3. COPD
9. Bronchodilators Market, by End-users
9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics
10. Americas Bronchodilators Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Bronchodilators Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Bronchodilators Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AdvaCare Pharma
14.1.2. AMGIS Lifescience Ltd.
14.1.3. AstraZeneca PLC
14.1.4. Boehringer Ingelheim International GmbH
14.1.5. Cambrex Corporation
14.1.6. Catalent, Inc.
14.1.7. Cipla Limited
14.1.8. GlaxoSmithKline PLC
14.1.9. Glenmark Pharmaceuticals Limited
14.1.10. Hikma Pharmaceuticals PLC
14.1.11. Lupin Limited
14.1.12. Mylan Inc. by Viatris Inc.
14.1.13. Nephron Pharmaceuticals Corporation
14.1.14. Novartis AG
14.1.15. Perrigo Company PLC
14.1.16. Pfizer Inc.
14.1.17. Prasco Laboratories
14.1.18. Ralington Pharma LLP
14.1.19. Siemens Healthcare GmbH
14.1.20. Steris Healthcare Pvt. Ltd.
14.1.21. Sun Pharmaceutical Industries Limited
14.1.22. Teva Pharmaceutical Industries Ltd.
14.1.23. Thermo Fisher Scientific Inc.
14.1.24. Vectura Group PLC
14.1.25. Zydus Group
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. BRONCHODILATORS MARKET RESEARCH PROCESS
FIGURE 2. BRONCHODILATORS MARKET SIZE, 2023 VS 2030
FIGURE 3. BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BRONCHODILATORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BRONCHODILATORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BRONCHODILATORS MARKET DYNAMICS
FIGURE 7. BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 12. BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 14. BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us